lobbying_activities: 2032095

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2032095	ce5fc93c-8e31-4a48-b482-c888e9c6fef4	Q3	APOTEX CORP.	310973	APOTEX CORP.	2017	third_quarter	PHA	HR 2430, the FDA Reauthorization Act of 2017, Title VIII, Improving Generic Drug Access, provisions relating to enhancing the generic drug approval process, spurring the development and approval of generic versions of drugs with limited competition, and generic drug exclusivity; and HR 2212/S. 974, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, and HR 2051, the Fair Access for Safe and Timely Generic Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals.	HOUSE OF REPRESENTATIVES,SENATE		110000	0	0	2017-10-19T09:46:26.920000-04:00